<DOC>
	<DOCNO>NCT02303990</DOCNO>
	<brief_summary>Phase I clinical trial hypofractionated radiotherapy isolated index lesion combination PD-1 inhibitor , Pembrolizumab patient metastatic cancer fail anti-PD-1 therapy ( melanoma NSCLC ) patient metastatic cancer progress least one regimen systemic therapy ( breast , pancreas , ) .</brief_summary>
	<brief_title>RADVAX : A Stratified Phase I Trial Pembrolizumab With Hypofractionated Radiotherapy Patients With Advanced Metastatic Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial . Be 18 year age day sign informed consent . Histologically confirm diagnosis cancer per cohort specification Stage IV cancer AJCC stag criterion ( except pancreatic cancer cohort ) Locally advanced metastatic pancreatic cancer pancreatic cancer cohort Progression disease antiPD1 antiPDL1 therapy melanoma NSCLC patient . For group , patient must meet follow criterion : 1 . Received least 2 dos antiPD1 antiPDL1 therapy 2 . Had progressive disease document radiologically RECIST v1.1 criterion . Progression refractory disease least one regimen therapy metastatic disease breast pancreatic cancer cohort Presence index lesion &gt; 1 cm amenable hypofractionated radiotherapy Patients metastatic cancer must least one lesion outside radiation field measure great one cm follow RECIST 1.1 . This lesion , close radiated lesion , must receive 10 % dose prescribed target lesion . Have provide tissue archival tissue sample newly obtain core excisional biopsy tumor lesion . Have performance status 0 1 ECOG Performance Scale . Ability tolerate hypofractionated radiation therapy ( e.g . lie flat hold position ) Demonstrate adequate organ function , screen lab perform within 14 day treatment initiation . Adequate Organ Function Laboratory Values System Laboratory Value Hematological Absolute neutrophil count ( ANC ) ≥1,500 /mcL Platelets ≥100,000 / mcL Hemoglobin ≥9 g/dL ≥5.6 mmol/L Renal Serum creatinine OR Measured calculateda creatinine clearance ( GFR also use place creatinine CrCl ) 1.5 X upper limit normal ( ULN ) OR ≥60 mL/min subject creatinine level &gt; 1.5 X institutional ULN Hepatic Serum total bilirubin 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) 2.5 X ULN OR 5 X ULN subject liver metastasis Creatinine clearance calculate per institutional standard Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . Female subject childbearing potential willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Male subject agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . Exclusion Criteria The subject must exclude participate trial subject : Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Systemic steroid administer specifically premedication chemotherapy infusion radiotherapy allow . Has prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent . Note : Subjects ≤ Grade 2 neuropathy exception criterion may qualify study . Note : If subject receive major surgery , must recover adequately toxicity and/or complication intervention prior start therapy . A history prior radiotherapy precludes delivery hypofractionated radiotherapy Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat brain metastasis may participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . Has active automimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Subjects vitiligo resolve childhood asthma/atopy would exception rule . Subjects require intermittent use bronchodilator local steroid injection would exclude study . Subjects hypothyroidism stable hormone replacement Sjogren 's syndrome exclude study . Has evidence interstitial lung disease active , noninfectious pneumonitis . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>